Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase II Study of Pre-Operative Pegylated Liposomal Doxorubicin (PLD), Paclitaxel, and Trastuzumab in Patients With Operable Breast Cancer Over-expressing Her2-neu

NCT00518583 is registered in ClinicalTrials.gov with Aptium Oncology Research Network as lead sponsor.

NCT NCT00518583
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00518583 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase II Study of Pre-Operative Pegylated Liposomal Doxorubicin (PLD), Paclitaxel, and Trastuzumab in Patients With Operable Breast Cancer Over-expressing Her2-neu
Lead sponsor
Aptium Oncology Research Network
Phase
Phase 2
Overall status
Unknown status
Start date
October 31, 2006
Completion date
September 30, 2009
Enrollment
30 (estimated)
Sites
9

Conditions

As the registry lists them; a condition with its own page is linked.

breast cancer